

Palazestrant

Chemical Properties

CAS No. : 2092925-89-6


Formula: C₂₈H₃₆FN₃O

Molecular Weight: 449.6

Storage: Store at low temperature, Keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity. Palazestrant inhibits 17β-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research.
Targets(IC50)	Estrogen Receptor/ERR, Estrogen/progestogen Receptor

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2242 mL	11.121 mL	22.242 mL
5 mM	0.4448 mL	2.2242 mL	4.4484 mL
10 mM	0.2224 mL	1.1121 mL	2.2242 mL
50 mM	0.0445 mL	0.2224 mL	0.4448 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Parisian AD, et al. Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination. Mol Cancer Ther. 2024 Mar 4;23(3): 285-300.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481